For novel technologies like photobioreactors, infrastructure is scarce. Companies must partner with separate CMOs for upstream cultivation and downstream processing to reach initial commercial revenue before building their own integrated facilities.

Breakthroughs in bioprocessing occur at the intersection of molecular biology and process engineering. The most effective approach is an iterative cycle: engineer a strain for specific process needs, test it in a real bioreactor (not just a flask), and use that performance data to inform the next round of strain improvement.

In biomanufacturing, purifying a product is a major cost. Using an organism that secretes the product directly into the media eliminates the need for cell lysis and reduces endotoxin concerns. This simplification of downstream processing can cut total production costs by 25-33%, a significant competitive advantage.

Industrial biotech startups often fail trying to scale cost-effectively. Since customers rarely pay a premium for sustainability alone, directly replacing a cheap petrochemical is a losing battle. A better strategy is to develop unique products with novel functionalities.

To make commodity products like cocoa economically viable, California Cultured rejects expensive stainless-steel bioreactors (costing up to $1M). Instead, they use simple plastic tanks costing only a few thousand dollars. This drastically reduces CapEx and is a fundamental shift in biomanufacturing philosophy for low-margin goods.

The use of low-cost, scalable plastic tank bioreactors eliminates the need for traditional, expensive GMP facilities. This allows companies to convert cheap, underutilized office space into production labs, enabling a novel business model of decentralized, onshore manufacturing that dramatically lowers real estate and operational costs.

Unlike traditional fermentation where moving to larger tanks introduces significant process variability, photosynthetic systems using photobioreactors scale modularly. Companies can simply add more units ("scaling out"), which minimizes performance differences and de-risks the transition to commercial-scale manufacturing.

Silkworm biomanufacturing offers incredible production density, with one pupa producing 10-20 mg of protein. Scaling requires simply adding more pupae ('scaling out') rather than building larger facilities ('scaling up'), enabling decentralized, small-footprint manufacturing.

For over a decade, slow growth rates and poor yields made cyanobacteria commercially unfeasible. The recent discovery of a faster-growing strain, combined with new genetic modification tools, has finally unlocked its industrial potential, closing the efficiency gap with established microbes like E. coli.